About Us
Theratechnologies was founded in 1993 and currently employs more than 100 people in Canada, the United States and Europe. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV.
Our History
A strong background in HIV:
Scientists at Theratechnologies discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the U.S. Food and Drug Administration (FDA).
EGRIFTA® was first marketed in the U.S. by a third-party commercial partner. In 2014, Theratechnologies reoriented its business model to become a commercial-stage biopharmaceutical company and regained U.S. commercial rights.
In 2016, the Company concluded an agreement to acquire the commercial rights to Trogarzo® in the U.S, and other markets. Trogarzo® was approved by the FDA in 2018 and was quickly adopted by physicians to treat people living with a persistent HIV viral load.
On October 3, 2022, the FDA approved an IV push method of administration of Trogarzo®.
For full prescribing information and safety information on our products please visit: www.trogarzo.com www.egriftasv.com www.egriftawr.com
Mission
To provide hope to healthcare practitioners and patients by developing and commercializing cutting-edge treatments that address unmet medical needs.
Vision
To be a biopharmaceutical company which successfully brings to market exceptional innovations.